Keywords
Leprosy
Leprosy, Multibacillary
Drug Therapy, Combination
Leprosy, Multibacillary
Drug Therapy, Combination
How to Cite
1.
Marques GF, Barreto JA, Sousa JMP, Brandão LSG. Alternative treatment of multibacillary leprosy in a case of hepatotoxicity during multidrug therapy. Hansen. Int. [Internet]. 2012 Nov. 30 [cited 2024 Nov. 23];37(2):81-5. Available from: https://periodicos.saude.sp.gov.br/hansenologia/article/view/36202
Abstract
The combination of dapsone, rifampicin and clofazimine has proven quite effective in the treatment of multibacillary leprosy, however dapsone is responsible for numerous side effects. We report a case of hepatoxocidade during multidrug therapy, successfully treated with the introduction of alternative treatment with rifampicin, clofazimine and ofloxacin.
References
1 - Goulart IMB, Arbex GL, Carneiro MH, Rodrigues MS, Gadia R. Adverse effects of multi drug therapy in leprosy patients: a five-year survey at a Health Centre of the Federal University of Uberlandia. Rev Soc Bras Med Trop. 2002;35(5):453-60.
2 - Opromolla DVA. Terapêutica da hanseníase. Medicina. 1997;30:345-50.
3 - Singh H, Nel B, Dey V, Tiwari P, Dulhani N. Adverse effects of multi-drug therapy in leprosy, a two years’ experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur). Lepr Rev. 2011;82(1):17-24.
4 - Ura S. Estudo terapêutico comparando a associação de rifampicina, ofloxacina e minociclina com a associação rifampicina, clofazimina e dapsona em pacientes com hanseníase multibacilar [dissertação]. Botucatu: Universidade Estadual Paulista; 2007. 59p.
5 - BRASIL. Ministério da Saúde. Gabinete do Ministro. Portaria n° 3125, de 7 de outubro de 2010. Aprova as diretrizes para vigilância, atenção e controle da hanseníase. Diário Oficial [da] República Federativa do Brasil, Poder Executivo, Brasília, DF, 15 out. 2010. Seção 1, p.55.
6 - Kaluarachchi SI, Fernandopulle BM, Gunawardane BP. Hepatic and hematological adverse reactions associated with the use of multidrug therapy in leprosy - a five year retrospective study. Indian J Lepr. 2001;73(2):121-9.
7 - Richardus JH, Smith TC. Icreased incidence in leprosy of hypersensitivity reactions to dapsona after introduction of multidrug therapy. Lepr Rev. 1989;60:267-73.
2 - Opromolla DVA. Terapêutica da hanseníase. Medicina. 1997;30:345-50.
3 - Singh H, Nel B, Dey V, Tiwari P, Dulhani N. Adverse effects of multi-drug therapy in leprosy, a two years’ experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur). Lepr Rev. 2011;82(1):17-24.
4 - Ura S. Estudo terapêutico comparando a associação de rifampicina, ofloxacina e minociclina com a associação rifampicina, clofazimina e dapsona em pacientes com hanseníase multibacilar [dissertação]. Botucatu: Universidade Estadual Paulista; 2007. 59p.
5 - BRASIL. Ministério da Saúde. Gabinete do Ministro. Portaria n° 3125, de 7 de outubro de 2010. Aprova as diretrizes para vigilância, atenção e controle da hanseníase. Diário Oficial [da] República Federativa do Brasil, Poder Executivo, Brasília, DF, 15 out. 2010. Seção 1, p.55.
6 - Kaluarachchi SI, Fernandopulle BM, Gunawardane BP. Hepatic and hematological adverse reactions associated with the use of multidrug therapy in leprosy - a five year retrospective study. Indian J Lepr. 2001;73(2):121-9.
7 - Richardus JH, Smith TC. Icreased incidence in leprosy of hypersensitivity reactions to dapsona after introduction of multidrug therapy. Lepr Rev. 1989;60:267-73.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Downloads
Download data is not yet available.
